<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890448</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-475_310</org_study_id>
    <secondary_id>2008-006906-41</secondary_id>
    <secondary_id>U1111-1112-3768</secondary_id>
    <secondary_id>DOH-27-0410-2857</secondary_id>
    <nct_id>NCT00890448</nct_id>
  </id_info>
  <brief_title>Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate</brief_title>
  <official_title>A Modified Case Control Study to Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the genetic contribution to the mechanism of
      lapaquistat acetate- induced hepatic abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a modified case control study to investigate the association of genotype with
      phenotype in subjects who experienced alanine aminotransferase and bilirubin derangements
      following exposure to lapaquistat acetate.

      The DNA profile of subjects who experienced significant biochemical hepatic derangement
      following exposure to lapaquistat acetate (cases) will be compared with a population of
      pre-genotyped untreated individuals (controls) from a public database. The DNA from subjects
      who had hepatic derangement during lapaquistat acetate studies, in the absence of exposure to
      lapaquistat acetate, will be stored. If data from the subjects exposed to lapaquistat acetate
      indicates that there is a genetic marker of interest, the stored DNA from non-exposed
      subjects will be assayed to further investigate the signal. One 10 mL sample of whole blood
      will be collected in plastic K2EDTA tube, after informed consent has been obtained.

      Each subject will sign the informed consent document prior to undergoing the study-related
      procedure. One 10 mL sample of whole blood will be collected from each subject. Extracted DNA
      will be analyzed using a whole genome scan approach as well as a candidate gene approach.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Whole genome scanning using the Illumina 1M chip.</measure>
    <time_frame>Visit 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole genome scanning using the Affymetrix 500K array chip.</measure>
    <time_frame>Visit 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Candidate gene scanning using the Affymetrix Drug Metabolizing Enzymes and Transporter (DMET) array.</measure>
    <time_frame>Visit 2</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>Lapaquistat acetate participants</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacogenomic whole blood sampling</intervention_name>
    <description>10 mL, whole blood, one sample on Visit 2</description>
    <arm_group_label>Lapaquistat acetate participants</arm_group_label>
    <other_name>TAK-475</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pharmacogenomic whole blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who participated in lapaquistat acetate phase 2 and phase 3 clinical studies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has experienced an alanine aminotransferase level greater than or equal to 5 times the
             upper limit of normal, or concurrent elevation of alanine aminotransferase greater
             than or equal to 3 times the upper limit of normal and bilirubin greater than or equal
             to 2 times the upper limit of normal while participating in lapaquistat acetate
             clinical studies.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-Foy</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Havírov-Šumbark</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Žilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alanine Transaminase elevation</keyword>
  <keyword>Genetic Markers</keyword>
  <keyword>DNA Markers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

